Journal of the Neurological Sciences
Volume 194, Issue 1 , Pages 29-34 , 15 February 2002

Expression of OX40 in muscles of polymyositis and granulomatous myopathy

  • Maki Tateyama

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +81-22-717-7189; fax: +81-22-717-7192
    • Department of Neurology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
    • ,
  • Kazuo Fujihara

      Affiliations

    • Department of Neurology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
    • ,
  • Naoto Ishii

      Affiliations

    • Department of Immunology, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • Kazuo Sugamura

      Affiliations

    • Department of Immunology, Tohoku University School of Medicine, Sendai, Japan
    • ,
  • Yoshiaki Onodera

      Affiliations

    • Department of Neurology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan
    • ,
  • Yasuto Itoyama

      Affiliations

    • Department of Neurology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

Received 26 June 2001 ,Revised 10 October 2001 ,Accepted 6 November 2001.

References 

  1. Baum PR, Gayle RB, Ramsdell F, Srinivasan S, Sorensen RA, Watson ML, et al.  Molecular characterization of murine and human OX40–OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 1994;13:3992–4001
  2. Stüber E, Neurath M, Calderhead D, Fell HP, Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity. 1995;2:507–521
  3. Moffatt S, Higashimura N, Sugamura K. CD134 (OX40) Workshop panel report. In:  Kishimoto T,  Kikutani H,  von dem Borne AEGK,  Goyert SM,  Mason DY,  Miyasaka M,  Moretta L,  Okumura K,  Shaw S,  Springer TA,  Sugamura K,  Zola H editor. Leucocyte typing VI. New York: Oxford Univ. Press; 1995;p. 869–871
  4. Gramaglia I, Weinberg AD, Lemon M, Croft M. OX40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998;161:6510–6517
  5. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 2000;165:3043–3050
  6. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, et al.  Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 2000;191:365–374
  7. Akiba H, Miyahara Y, Atsuta M, Takeda K, Nohara C, Futagawa T, et al.  Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 2000;191:375–380
  8. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, Maeda M, et al.  The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 1996;183:2185–2195
  9. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T cell activation antigen, OX40, identifies alloreactive T cells in acute graft versus host disease. Blood. 1997;89:4652–4658
  10. Dürkop H, Latza U, Himmelreich P, Stein H. Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues. Br. J. Haematol. 1995;91:927–931
  11. Brugnoni D, Bettinardi A, Malacarne F, Airò P, Cattaneo R. CD134/OX40 expression by synovial fluid CD4+ T lymphocytes in chronic synovitis. Br. J. Rheumatol. 1998;37:584–585
  12. Higgins LM, McDonald SAC, Whittle N, Crockett N, Shields JG, MacDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40–OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40–IgG fusion protein, but not with an OX40 ligand–IgG fusion protein. J. Immunol. 1999;162:486–493
  13. Stüber E, Büschenfeld A, Lüttges J, von Freier A, Arendt T, Fölsch UR. The expression of OX40 in immunologically mediated diseases of the gastrointestinal tract (celiac disease, Crohn's disease, ulcerative colitis). Eur. J. Clin. Invest. 2000;30:594–599
  14. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, et al.  Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. 1996;2:183–189
  15. Weinberg AD. Antibodies to OX40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease. Mol. Med. Today. 1998;4:76–83
  16. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In:  Engel AG,  Franzini-Armstrong C editor. Myology. 2nd ed.. New York: McGraw-Hill; 1994;p. 1335–1383
  17. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann. Neurol. 1988;23:64–72
  18. Olsson T, Henriksson KG, Klareskog L, Forsum U. HLA-DR expression, T lymphocyte phenotypes, OKM1 and OKT9 reactive cells in inflammatory myopathy. Muscle Nerve. 1985;8:419–425
  19. Pedrol E, Grau JM, Casademont J, Cid MC, Masanés F, Fernandez-Sola J, et al.  Idiopathic inflammatory myopathies: immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin. Neuropathol. 1995;14:179–184
  20. Bartoccioni E, Gallucci S, Scuderi F, Ricci E, Servidei S, Broccolini A, et al.  MHC class I, MHC class II and intercellular adhesion molecule-1 (ICAM-1) expression in inflammatory myopathies. Clin. Exp. Immunol. 1994;95:166–172
  21. Tews DS, Pongratz DE. Immunohistological analysis of sarcoid myopathy. J. Neurol., Neurosurg. Psychiatry. 1995;59:322–325
  22. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies: I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 1984;16:193–208
  23. De Bleecker JL, Engel AG. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am. J. Pathol. 1995;146:1178–1187
  24. Ménard DB, Haddad H, Blain JG, Beaudry R, Devroede G, Massé S. Granulomatous myositis and myopathy associated with Crohn's colitis. N. Engl. J. Med. 1976;818–819
  25. Pettersson T. Rheumatic features of sarcoidosis. Curr. Opin. Rheumatol. 1997;9:62–67
  26. Takanashi T, Suzuki Y, Yoshino Y, Nonaka I. Granulomatous myositis: pathologic reevaluation by immunohistochemical analysis of infiltrating mononuclear cells. J. Neurol. Sci. 1997;145:41–47
  27. Onodera J, Nagata T, Fujihara K, Ohuchi M, Ishii N, Sugamura K, et al.  Expression of OX40 and OX40 ligand (gp34) in the normal and myasthenic thymus. Acta Neurol. Scand. 2000;102:236–243
  28. Chilosi M, Menestrina F, Capelli P, Montagna L, Lestani M, Pizzolo G, et al.  Immunohistochemical analysis of sarcoid granulomas. Am. J. Pathol. 1988;131:191–198
  29. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasculitis Diffuse Lung Dis. 1999;16:24–31
  30. Lane P. Role of OX40 signals in coordinating CD4 T cells selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells. J. Exp. Med. 2000;191:201–205
  31. Dalakas MC. Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin. Neuropharmacol. 1992;15:327–351
  32. Wu M. Are immunoconjugates useful for therapy with autoimmune diseases?. Int. J. Immunopharmacol. 1997;19:83–93

PII: S0022-510X(01)00668-2

Journal of the Neurological Sciences
Volume 194, Issue 1 , Pages 29-34 , 15 February 2002

Article Tools

* Image Usage & Resolution